Assessment of effect of different doses of buprenorphine (16,32 mg) on reduction of anxiety level and craving in opioid dependents
Not Applicable
Recruiting
- Conditions
- Opioid dependency.Mental and behavioral disorders due to use of opioids
- Registration Number
- IRCT2017082225160N11
- Lead Sponsor
- Vice chancellor of Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 60
Inclusion Criteria
Inclusion Criteria: age between 16 to 60 y/o; informed consent; Opioid dependence Exclusion criteria:Patients unwilling to participate at beginning or during the study; use of other substances except Opioid as of the main substance
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of withdrawal symptoms in opiod dependents and find the best choice. Timepoint: before the first dose and first day to 4 days. Method of measurement: by interview based on DSM-5 and questionnaire (Craving and withdrawal questionnaire).
- Secondary Outcome Measures
Name Time Method Change of anxiety, depression in opiod dependents and find the best choice, suicidal thoughts. Timepoint: before the first dose and first day to 4 days. Method of measurement: by interview based on DSM-5 criteria and questionnaires (Ham-A, BSSI, BDI).